RecruitingPhase 2Phase 3NCT06181422
Metformin and Lactoferrin in Sepsis in Icu
Comparative Study to Evaluate the Safety and Possible Efficacy of Metformin Versus Lactoferrin in ICU Patients With
Sponsor
Tanta University
Enrollment
60 participants
Start Date
Apr 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria3
- Age more than 18 years old.
- A diagnosis of sepsis according to the latest Sepsis definition.11
- Estimated GFR \>45 ml/minute.
Exclusion Criteria3
- Pregnancy and breast feeding.
- End stage hepatic disease.
- End stage renal disease -
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMetformin
metformin 500 mg
DRUGLactoferrin
lactoferrin 100 mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06181422
Related Trials
Stop Sepsis Through Home Monitoring Cooperative
NCT069209791 location
Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis
NCT065628031 location
Aminoglycosides in Early Sepsis
NCT067126415 locations
NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot
NCT066462501 location
Organ Dysfunction Score for Obstetric Patients
NCT0706802218 locations